Management of liver metastasis from neuroendocrine tumors routinely includes an interventional radiologist. Hepatic artery embolization, either bland (transarterial embolization) or with chemotherapy (transarterial chemoembolization), has been shown to improve response rates in neuroendocrine metastases to the liver. Radiofrequency ablation, cryotherapy, and percutaneous alcohol ablation are important adjuncts or alternative treatments to surgical debulking. In this article, the authors examine important techniques in the armamentarium of the interventional radiologist. (JNCCN 2009;7:765-772) with chemotherapy added (alternating doxorubicin plus dacarbazine and streptozocin plus fluorouracil).
with chemotherapy added (alternating doxorubicin plus dacarbazine and streptozocin plus fluorouracil). 1 Over the ensuing decades, selective lobar hepatic artery embolization or chemoembolization was found to be significantly more tolerable than surgical ligation. 2, 3 Several ablative techniques were also developed over the past 2 decades, causing interventional radiologists to become important members of the multidisciplinary team managing patients with neuroendocrine tumors. These developments are reflected in the current guidelines of the NCCN, which list both embolization and ablative techniques for managing patients with metastatic neuroendocrine tumors ( Table 1) . 4 
Hepatic Artery Embolization
Although surgery remains the preferred procedure for patients with localized hepatic metastasis, it is rarely an option (10%-20%) for those with disseminated or multifocal disease. [5] [6] [7] Although liver transplantation has been reported in sporadic series for multifocal metastatic neuroendocrine tumors, the lack of donor livers and variable survival rate (36%-87%) 6, 8, 9 reported make it a nonviable option for most patients. The rationale for hepatic artery embolization is based on the observation that these hypervascular tumors derive most of their blood supply from the hepatic artery. 5, 10 Moreover, hepatic metastases are known to compress adjacent portal sinusoids, which are the primary blood supply sites for normal liver tissue. In patients with progressive or symptomatic metastases predominantly confined to the liver, embolization or chemoembolization of the hepatic artery can be recommended as first-line therapy.
Typically, each lobe of the liver is embolized selectively.
The liver is the predominant site of metastatic disease in gastrointestinal neuroendocrine tumors. In the early 1980s, hepatic artery ligation was recommended for management of patients with symptomatic carcinoid syndrome. 1 In fact, early studies by Moertel et al. 1 showed objective regressions in 60% of patients with metastatic carcinoid to the liver using occlusion alone versus 80% saline (0.9%) combined with 10 mL of iodized oil, which is injected into the subselected right or left hepatic artery. The embolization procedure is performed until near complete stasis of flow. Usually the liver lobe with the bulkiest disease is embolized first. Antiemetics and adequate analgesia should be provided, and preoperative intravenous hydration is important. Perioperative antibiotics should be administered (e.g., levofloxacin and flagyl) for at least 72 hours to prevent abscess formation. Individual embolizations are spaced 4 weeks apart, and most patients complete their embolizations in 2 or 3 stages. 11 Follow-up imaging studies are typically performed 1 to 2 months after the last embolization.
Minor complications are common, such as transient nausea, vomiting (50%-70%), abdominal pain (50%-60%), and fevers (30%-60%).
11 Hepatic transaminases typically increase, peaking 2 to 3 days after each embolization. 11 Most side effects resolve within 1 week. Acute hypertension is occasionally observed in patients with carcinoid syndrome during or immediately after the embolization procedure. Elevated liver enzymes are also seen (100% peak usually within 2-3 days). Severe complications, such as gastric perforation, gastritis, bleeding peptic ulcers, and duodenitis, can usually be avoided with highly selective catheterization. Hepatic and renal failure has also been reported after repeated embolization treatments. 12 Thus, the entire liver can be treated in 2 to 3 stages, depending on the extent of disease. Chemotherapeutic agents are often added to the embolic material (doxorubicin, streptozocin); however, whether addition of chemotherapy improves outcomes is still uncertain.
Embolization Procedure
A diagnostic celiac angiogram is performed to identify the hepatic vasculature, patency of the portal vein, and number and location of hepatic metastases. Presence of portal vein occlusion and ascites are considered relative contraindications for the procedure. A superior mesenteric arteriogram is performed in the presence of a replaced or accessory hepatic artery. Subcutaneous octreotide is often administered immediately before the procedure in patients with the carcinoid syndrome to prevent acute release of serotonin into the circulation. Subselective catheterization of the right or left hepatic artery is performed using an angled 5 Fr catheter or 3 Fr microcatheter coaxially through the 5 Fr angled catheter placed in the origin of the celiac artery or superior mesenteric artery.
Embolization is performed under fluoroscopy. Various particulate materials have been used, including 250-to 355-μm diameter polyvinyl alcohol particles and 500-to 700-μm diameter microspheres. For chemoembolization, an emulsion of a cytotoxic drug such as doxorubicin, mitomycin C, or cisplatin, or a combination of these, is dissolved in 10 mL of normal Hepatic arterial embolization has been shown to provide symptomatic relief in 59% to 100% of cases (Table 2 ). Symptomatic responses occur as a result of reduction in hepatic tumor burden and decrease of hormonal output in functional tumors. [13] [14] [15] [16] For example, major decreases in 5-hydroxyindoleacetic acid (5-HIAA) levels (> 50% reduction) occur in 51% to 91% of patients with carcinoid syndrome. [16] [17] [18] [19] [20] Objective tumor responses have been noted in 33% to 80% of patients (Table 3 ). This is a heteroge- resin and is converted to yttrium 90 through neutron bombardment. Patients with myelosuppression and renal failure are generally excluded. Preprocedural studies, including visceral angiogram for mapping the vascular supply to the liver, is performed approximately a week before radioembolization. Any vessels supplying the gastrointestinal tract that must be avoided are embolized before treatment. Technetium 99m isotope-labeled macro-albumin similar in size to the radioembolization particle is then infused through the catheter, and single-photon emission computed tomography (SPECT) gamma imaging is obtained to evaluate for possible shunting of microspheres to the lungs or gastrointestinal tract. The approach to radioembolization is similar to hepatic artery embolization. However, the goal of radioembolization is to cause tumor necrosis through radiation exposure. Cell death through radiation requires normal oxygen tension. Therefore, stasis of flow is avoided during radioembolization. Radioembolic agents are typically infused to both lobes rather than staged using a unilobar approach.
In a retrospective multi-institutional study, radioembolization showed complete imaging response in 2.7% of cases, partial response in 60.5%, stable disease in 22.7%, disease progression in 4.9%, and median survival of 70 months. 47 A study comparing the use of glass versus resin microspheres for metastatic neuroendocrine tumors showed a 92% and 94% response rate at 6 months, with a median survival of 22 and 28 months, respectively. Grade III/IV toxicity was experienced by 14% of patients. 49 The side effect profile includes renal failure, postembolization syndrome, and bone marrow suppression. The postembolization syndrome occurs in only 18% of cases due to arterial flow stasis.
Radiofrequency Ablation, Cryoablation, and Percutaneous Alcohol Injection
Patients with limited numbers of unresectable liver metastases may benefit from interventional ablative techniques. Tumor ablations are often performed intraoperatively, in conjunction with surgical resection. Alternatively, they may be performed percutaneously, depending on the number and location of the hepatic metastases.
Radiofrequency Ablation
Radiofrequency ablation (RFA) involves converting radiofrequency waves to heat using a high alternating current of 460 kHz, which passes from an uninsulated tip into surrounding tissues and causes ionic vibration after the change in the direction of the current. Friction heating caused by the ionic vibration and tumor death occurs at around 60 o C. The size of the ablation zone is dependent on the size of the probe. Currently the largest ablation zone is approximately 7 cm.
Technique
RFA can be performed under local anesthesia with sedation or under general anesthesia. Using ultrasound or CT image guidance, an RFA needle probe is inserted into the liver metastasis. The position of the probe is confirmed on multiplanar imaging to verify true centricity of the probe. The tines of the probe (e.g., RITA Angiodynamics, Queensbury, New York; Cooltip RFA device, Valleylab, Colorado; RF 3000, Boston Scientific, Natick, Massachusetts) are then advanced to generate a thermal ablation zone, including the tumor and a margin. Anatomic proximity to blood vessels can act as a heat sink, thus causing loss of effect, and temperatures are continuously monitored on each of the probe tines. Once adequate heating is achieved for the specified duration based on size of the ablation zone, the tines are withdrawn and the probe removed. Similar procedures are repeated for other lesions.
Patients are usually monitored postoperatively for pain and fevers. Other complications include bile leakage and pleural effusion. 50 Radiologic followup is established and the images are reviewed by an experienced radiologist.
Response
Complete or significant symptom response has been shown in 69% to 80% of patients treated with RFA, and local control was achieved in 74% of the symptomatic patients. 12 Complications associated with RFA are usually restricted to those at the site of needle entry, such as pneumothorax and neuritis, in addition to liver abscesses.
Percutaneous Ethanol Injection
Percutaneous alcohol ablation has been described in the treatment of hepatocellular carcinoma and metastatic colorectal adenocarcinomas, in which necrosis is achieved in 50% of cases. 51, 52 Alcohol acts by causing coagulative necrosis, which then leads to thrombosis of small vessels accompanied by formation of fibrotic tissue. The main concern regarding ethanol gral to multidisciplinary care. Available techniques for patients with disseminated hepatic metastases include hepatic arterial embolization, chemoembolization, and radioembolization. RFA, cryotherapy, and, to a lesser extent, ethanol therapy serve as adjuncts to surgical cytoreduction when necessary.
use is its inhomogenous distribution. Overall, percutaneous ethanol injection has largely been replaced by RFA, which typically achieves necrosis in fewer sessions and is associated with lower rates of recurrence. 52, 53 Therefore ethanol ablation is generally reserved for metastases abutting large vessels susceptible to the heat-sink effect, and adjacent to central bile ducts in which strictures can occur with RFA. 54 
Cryoablation
Cryoablation involves freezing and thawing of tumors, resulting in tumor ablation. [55] [56] [57] [58] [59] Cryotherapy can be used percutaneously or intraoperatively using intraoperative ultrasound and probes, and has become an important adjunct to surgical cytoreduction. Drawbacks include the large size of the probe, which causes increased risk for hemorrhage and higher rates of complications for larger metastases. More recently, smaller-gauge cryoprobes for percutaneous ablation, which allow placement of multiple probes, have been introduced simultaneously (PerCryo, Endocare Inc, Ervine, California). Image guidance is improved with use of CT, which clearly delineates the iceball for accurate visualization of the zone of treatment. Limited data remain for cryoablation treatment of neuroendocrine liver metastases, but it has potential and requires further investigation by interventional radiologists.
Laser Interstitial Thermotherapy
Using a Nd-YAG laser to create coagulative necrosis has been proposed for managing hepatic metastasis from neuroendocrine tumors. The laser fiber is introduced through a laser application kit, consisting of a cannulation needle, guide wire, sheath system with mandrin (10F, 20 cm in length), and special protective catheter (9F, 43 cm in length) that is closed at the end. This protective catheter, which is heat-resistant, prevents direct contact of the laser fiber with the tissue and enables safe and easy removal of the fiber post-therapy. The laser system is cooled with saline and therefore prevents carbonization of the laser fiber. The advantage of the laser application system is that it can be performed under MR guidance; this is of great value because the efficacy of the therapy can be evaluated simultaneously using MRI.
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Conclusions
The role of interventional radiologists in managing liver metastasis from neuroendocrine tumors is inte-
